These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24160295)

  • 1. Vitamin D: preventive and therapeutic potential in Parkinson's disease.
    Liu Y; Li YW; Tang YL; Liu X; Jiang JH; Li QG; Yuan JY
    Curr Drug Metab; 2013 Nov; 14(9):989-93. PubMed ID: 24160295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D and Parkinson's disease--a hypothesis.
    Newmark HL; Newmark J
    Mov Disord; 2007 Mar; 22(4):461-8. PubMed ID: 17230473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D and Parkinson's disease.
    Vinh Quôc Luong K; Thi Hoàng Nguyên L
    J Neurosci Res; 2012 Dec; 90(12):2227-36. PubMed ID: 22930493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease.
    Miyazaki I; Asanuma M
    Curr Pharm Des; 2017; 23(33):4936-4947. PubMed ID: 28699520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of vitamin D on brain development and adult brain function.
    Kesby JP; Eyles DW; Burne TH; McGrath JJ
    Mol Cell Endocrinol; 2011 Dec; 347(1-2):121-7. PubMed ID: 21664231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review of the Relationship between Vitamin D and Parkinson's Disease.
    Rimmelzwaan LM; van Schoor NM; Lips P; Berendse HW; Eekhoff EM
    J Parkinsons Dis; 2016; 6(1):29-37. PubMed ID: 26756741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential.
    Liu C; Xue Y; Liu MF; Wang Y; Chen L
    Neurochem Int; 2020 Sep; 138():104754. PubMed ID: 32422324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
    Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of vitamin D and Parkinson's disease.
    Peterson AL
    Maturitas; 2014 May; 78(1):40-4. PubMed ID: 24685289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of estrogens in Parkinson's disease].
    Dziedziejko V; Białecka M; Machoy-Mokrzyńska A; Kłodowska-Duda G; Chlubek D
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():627-33. PubMed ID: 20097949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Vitamin D₃ in the Development and Neuroprotection of Midbrain Dopamine Neurons.
    Orme RP; Middleditch C; Waite L; Fricker RA
    Vitam Horm; 2016; 100():273-97. PubMed ID: 26827956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
    Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
    Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
    Jellinger KA
    J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress and antioxidant therapy in Parkinson's disease.
    Ebadi M; Srinivasan SK; Baxi MD
    Prog Neurobiol; 1996 Jan; 48(1):1-19. PubMed ID: 8830346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease.
    Lewis MM; Huang X; Nichols DE; Mailman RB
    CNS Neurol Disord Drug Targets; 2006 Jun; 5(3):345-53. PubMed ID: 16787233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.